Journal of Foot and Ankle Research (Jan 2023)

Decline in health‐related quality of life and foot and ankle patient reported outcomes measures in patients with haemophilia and ankle haemarthropathy

  • Richard A. Wilkins,
  • Heidi J. Siddle,
  • Graham J. Chapman,
  • Elizabeth Horn,
  • Rebecca Walwyn,
  • Anthony C. Redmond

DOI
https://doi.org/10.1186/s13047-023-00611-5
Journal volume & issue
Vol. 16, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract Background Haemophilia is an X‐linked recessive genetic disorder characterised by bleeding within soft tissue and joints. The ankle is disproportionally affected by haemarthropathy when compared to the elbows and knees; reported as the most affected joints in patients with haemophilia. Despite advances in treatment, patients still report ongoing pain and disability, however, the impact has not been evaluated, nor has the effect on health‐related quality of life (HRQoL) or foot and ankle patient‐reported outcome measures (PROMs). The primary aim of this study was to establish the impact of ankle haemarthropathy in patients with severe and moderate haemophilia A and B. Secondly to identify the clinical outcomes associated with a decline in HRQoL and foot and ankle PROMs. Methods A cross‐sectional multi‐centre questionnaire study was conducted across 18 haemophilia centres in England, Scotland and Wales with a recruitment target of 245 participants. The HAEMO‐QoL‐A and Manchester‐Oxford Foot Questionnaire (MOXFQ) (foot and ankle) with total and domain scores measured impact on HRQOL and foot and ankle outcomes. Demographics, clinical characteristics, ankle haemophilia joint health scores, multi‐joint haemarthropathy and Numerical Pain Rating Scales (NPRS) of “ankle pain over the past six months” were collected as a measure of chronic ankle pain. Results A total of 243 of 250 participants provided complete data. HAEMO‐QoL‐A and MOXFQ (foot and ankle) total and index scores indicated worse HRQoL with total scores ranging from a mean of 35.3 to 35.8 (100 best‐health) and 50.5 to 45.8 (0 best‐health) respectively. NPRS (mean (SD)) ranged from 5.0 (2.6) to 5.5 (2.5), with median (IQR) ankle haemophilia joint health score of 4.5 (1 to 12.5) to 6.0 (3.0 to 10.0) indicating moderate to severe levels of ankle haemarthropathy. Ankle NPRS over six months and inhibitor status were associated with decline in outcome. Conclusions HRQoL and foot and ankle PROMs were poor in participants with moderate to severe levels of ankle haemarthropathy. Pain was a major driver for decline in HRQoL and foot and ankle PROMs and use of NPRS has the potential to predict worsening HRQoL and PROMs at the ankle and other affected joints.

Keywords